Welcome Stuart Barich

We are excited to welcome Stuart “Stu” Barich as Managing Director and Head of Biotechnology in our US Healthcare Investment Banking group.  He will leverage his client experiences, past deal activities, and sector insights to focus on the Biotechnology sector. Stuart has 30+ years of experience in investment banking, focusing on Life Sciences.

Stuart joins us after a decade at Raymond James, where he was Managing Director.  He has participated in the successful completion of over 520 transactions during his career, covering a broad spectrum of equity and mergers and acquisitions. Prior to joining Raymond James, Stuart spent almost 10 years at Oppenheimer and five years at Leerink Swann completing numerous transactions for Biotechnology and Specialty Pharmaceutical companies. He previously directed the healthcare banking efforts at Oscar Gruss & Son and Auerbach, after beginning his career as a Corporate Finance Associate with Paine Webber.

Stuart has a BS in electrical engineering from the University of Rochester and an MBA with honors from Columbia Business School.

Based in New York City, Stuart will lead coverage efforts on companies within the biotechnology, specialty, and generic pharmaceutical sectors.. His appointment deepens the expertise of our current team while expanding our reach into biotechnology, an area with significant opportunities for continued ECM and M&A activity. His addition further strengthens our Healthcare franchise and reinforces our commitment to building a leading platform across high-growth sectors.